Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has become the first drug to be approved by the US Food and Drug Administration (FDA) as a treatment for noncirrhotic nonalcoholic ...

Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic ...

Barker et al [43] found improvement in steatosis, lobular inflammation, and portal/lobular fibrosis in the majority of the 19 patients studied. In addition, histopathologic criteria for NASH were ...

The presence of inflammation on liver biopsy is associated with the development of advanced fibrosis in NASH. The presence of acinar inflammation is essential for the histological diagnosis of ...

Driven by rising levels of obesity, NASH causes fibrosis and swelling in the liver and has become a leading concern in healthcare as increasing numbers of people with the condition advance to ...

Non-alcoholic steatohepatitis (NASH) is a widespread disease affecting up to ~12% of the US population – characterized by lipid accumulation in hepatocytes, infiltration of immune cells and fibrosis ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...

One such disease, nonalcoholic steatohepatitis (NASH), is characterized by dysregulated metabolism, inflammation and fibrosis. According to Axcella’s Chief Medical Officer and Executive Vice ...

The test is not for use in the diagnosis of NASH or for the staging of fibrosis. Please contact Siemens Healthineers directly for availability. The Enhanced Liver Fibrosis (ELF TM) Test is a non ...